Membrane-type matrix metalloprotease proteolysis cancer invasion EMT tumor microenvironment extracellular matrix A B S T R A C T Membrane-type matrix metalloproteases (MT-MMP) are pivotal regulators of cell invasion, growth and survival. Tethered to the cell membranes by a transmembrane domain or GPI-anchor, the six MT-MMPs can exert these functions via cell surface-associated extracellular matrix degradation or proteolytic protein processing, including shedding or release of signaling receptors, adhesion molecules, growth factors and other pericellular proteins. By interactions with signaling scaffold or cytoskeleton, the C-terminal cytoplasmic tail of the transmembrane MTMMPs further extends their functionality to signaling or structural relay. MT-MMPs are differentially expressed in cancer. The most extensively studied MMP14/MT1-MMP is induced in various cancers along malignant transformation via pathways activated by mutations in tumor suppressors or proto-oncogenes and changes in tumor microenvironment including cellular heterogeneity, extracellular matrix composition, tissue oxygenation, and inflammation. Classically such induction involves transcriptional programs related to epithelial-tomesenchymal transition. Besides inhibition by endogenous tissue inhibitors, MT-MMP activities are spatially and timely regulated at multiple levels by microtubular vesicular trafficking, dimerization/oligomerization, other interactions and localization in the actin-based invadosomes, in both tumor and the stroma. The functions of MT-MMPs are multifaceted within reciprocal cellular responses in the evolving tumor microenvironment, which poses the importance of these proteases beyond the central function as matrix scissors, and necessitates us to rethink MT-MMPs as dynamic signaling proteases of cancer.
Introduction
The main cause of cancer-associated mortality is metastasis to vital organs, which relies on cancer dissemination by interchangeable modes of cell invasion and growth. Such cellular plasticity also contributes to anticancer drug responses and development of resistance, representing a major challenge in current cancer research. Membrane-type matrix metalloproteases (MT-MMPs) are proteolytic enzymes responsible for the pericellular degradation of the basement membrane and interstitial extracellular matrix (ECM) to promote cancer invasion and growth [1, 2] . Moreover, these membrane-anchored proteases are important modulators of cell-cell communication and intracellular signaling as a result of e.g. shedding receptors, ligands, and adhesion molecules, or releasing growth factors in the tumor microenvironment (TME) [2] [3] [4] . Functions independent of the MT-MMP proteolytic activity have also been implicated in the regulation of tumor cell-cell communication and intracellular signaling [3, 5] . Based on these activities, MT-MMPs have emerged as dynamic regulators of cancer cell functions in the evolving TME to control phenotypic cell plasticity in cancer.
The six MT-MMPs belong to the family of 23 human secreted and membrane-anchored MMPs. The general MMP domain structure includes an N-terminal pro-domain that maintains the enzyme in latent form, a catalytic domain essential for protease activity, and a Cterminal hemopexin-like domain involved in e.g. oligomerization, substrate recognition and interactions with tissue inhibitors of matrix metalloproteases (TIMPs 1-4) [3, 6] . Among MT-MMPs, the four type I transmembrane proteases, MMP14 (MT1-MMP), MMP15 (MT2-MMP), MMP16 (MT3-MMP), and MMP24 (MT5-MMP), are anchored to the cell membrane via transmembrane (TM) domain followed by C-terminal cytoplasmic tail (CT) of~20 amino acids [2] . MMP17 (MT4-MMP) and MMP25 (MT6-MMP) are instead attached to the plasma membrane via glycosylphosphatidylinositol (GPI) anchor that concentrates them to glycolipid-enriched membrane microdomains [7] . A single MMP, MMP23, is synthesized as a type II transmembrane protein with several atypical features [8] . Herein we focus on the multifaceted regulation and functions of type I TM and GPI-anchored MT-MMPs elaborately harnessed by the tumor and stroma to impact cellular dynamics and tissue remodeling in cancer progression.
MT-MMP expressing cells in tumor microenvironment
Cancers in varying anatomical loci contain heterogeneous populations of cancer cells and stromal cells interacting in complex regulatory networks, which are reciprocally responsive to changes initiated by both malignant transformation and reactive stroma. MT-MMPs' involvement in this interplay is multifaceted and context-dependent as these membrane-tethered proteases are expressed in cancer cells as well as in different types of stromal cells, all of which demonstrate tremendous plasticity in response to tumor evolution, including the evolving microenvironment, both at the primary and metastatic sites.
The classical patterns of the most widely expressed MT-MMP, MMP14, in epithelial tumors such as breast and prostate carcinomas represent strong expression in either the cancer cells or stroma [9, 10] (Fig. 1A) . Indeed, besides malignant tumor cells, cancer-associated fibroblasts (CAF), macrophages and endothelial cells express MMP14 [1, 11, 12] . Bone marrow derived mesenchymal stromal/stem cells (MSC) that infiltrate into the developing TME, and have the potential to differentiate into various cell types, can also express high levels of MMP14 (Fig. 1B) (the highest MMP14 expressing normal cell; ist. medisapiens.com [13, 14] ).
The expression of other MT-MMPs in distinct cancer and stromal cell populations has not been comprehensively characterized (Fig. 1B) . Besides MMP14 with potent fibrinolytic and collagenolytic activities in vascular cells, MMP15 and MMP16 have, however, been found in endothelial cells during capillary tube formation [15] . MMP17, the first MT-MMP identified in leukocytes, has in turn been detected in inflammatory cells in lymph node metastases [7, 16, 17] . Little is known about the cell types expressing MMP24, first identified in the nervous system and brain tumors [18, 19] , whereas MMP25, also termed leukolysin, is prominently expressed by peripheral blood leukocytes and tumor infiltrating inflammatory cells such as neutrophils, as well as in hematological cancers [7, 20] .
Aside from human cancer expression data, mouse models have provided important insights on the MT-MMP expression and activities in tumor cells as well as in stroma during cancer progression. The cancer-promoting functions of tumor cell MMP14 have gained support from numerous tumor xenograft studies (see e.g [21] [22] [23] ). In MMTVPymT transgenic mouse mammary carcinoma model, stromal cells or CAFs instead induce MMP14, and genetic depletion of the stromal MMP14 enhances tumor growth but diminishes metastasis [24] . In a mouse colorectal cancer model, MMP14 is in turn induced in tumorassociated macrophages (TAM), whose depletion reduces tumor growth and impairs ECM remodeling [25] . Considering these results along with the classical patterns of tumor or stromal MMP14 induction observed in human carcinomas (Fig. 1A) , distinct cancers may employ either stromal (CAF or TAM) or cancer cell MMP14 for ECM remodeling and metastasis seeding. Since TAMs have recently emerged as efficient modifiers of collagenous tumor ECM [25] , the stromal function previously attributed mainly to CAFs, the cell-type specific changes in MT-MMP expression can reflect and affect the heterotypic signaling loops between CAFs, TAMs, and cancer cells relevant for tumorigenic processes, treatment responses and cancer relapse [26] .
MT-MMP expression in different cancer types
Human MT-MMP genes are located in different chromosomes except for MMP15 and MMP25 genes located in chromosome 16 (16q21 and 16p13, respectively). MMP14 gene is located in 14q11, MMP16 in 8q21, MMP17 in 12q24, and MMP24 in 20q11. Cancer-associated polymorphisms and mutations in MT-MMPs are rare with the highest mutation frequency of~1.2% in MMP16 (The Cancer Genome Atlas/TCGA and COSMIC; not shown). Copy number alterations (CNA) of MT-MMP genes are also relatively rare as assessed using TCGA data and cBio Cancer Genomics Portal [27, 28] (Fig. 2 ). MMP15 appears, however, more often deleted than amplified in tumor tissue, whereas MMP16 is amplified in several cancers with larger frequencies than any other MT-MMP (Fig. 2) .
Based on our systematic cross-cancer analysis of MT-MMP expression data, MMP14 expression is highest in mesenchymal cancers, sarcomas, and mesotheliomas, consistent with the high developmental MMP14 expression in cells of mesenchymal origin [29] (Fig. 3) . Therefore, the collagenolytic MMP14 activity can be particularly harnessed to drive invasion in the collagen-rich TMEs of these cancers. Accordingly, MMP14 expression is high also in melanoma, the cancer of melanocytes that display high motility during developmental invasion from the neural crest. These analogies of the pro-invasive MMP14 expression in cancer and development are consistent with the concept of spatiotemporally misguided re-ignition of the developmental transcriptional programs in cancer. In line with this, MMP15, expressed in developing epithelium [30, 31] , is induced in cancers of epithelial origin such as cholangiocarcinoma, in addition to the highest expression of this protease in testicular germ cell cancer (Fig. 3) . MMP16 expression is highest in brain tumors -gliomas and GBM, and in melanoma, again consistent with the reported developmental expression and functions of this protease in cells of neural crest origin [32, 33] (normal brain cells are among top five for MMP16 expression; ist.medisapiens.com [13] ), as well as with the pathological re-emergence in the TME of proteoglycan-based brain tissue (Fig. 3) . Interestingly, based on TCGA data, melanoma is also the cancer type with highest MMP17 expression (Fig. 3) . The expression of MMP24, initially described in brains and brain tumors, appears the strongest in mesothelioma, whereas malignancies of leukocytes rank among the top four cancers with MMP25 expression (Fig. 3) [18, 19] .
Altogether, these data suggest that cell lineage specificity and malignant transformation induced transcriptional programs dictate the MT-MMP expression over cancer-specific genetic changes in MTMMPs. For example, liver and ovarian cancers with frequent MMP16 amplifications (Fig. 2) are among the cancers with lowest MMP16 mRNA expression (Fig. 3) . Caution is, however, needed when interpreting these type of whole tumor expression data in terms of the cell of origin for the expression. For instance, MMP14 induction in tumor adjacent stroma, or tumor infiltration of the MMP25 and MMP17 expressing leukocytes, can have unpredictable effects on the relative MT-MMP expression detected in these tumor tissue biopsies.
MT-MMP regulation

Endogenous MT-MMP inhibitors
Proteolytic enzymes need rigorous control in normal physiology. The proteolytic activity of MMPs including MT-MMPs is controlled endogenously by tissue inhibitors of metalloproteases (TIMP1-4), which bind reversibly to active MMPs in 1:1 molar ratio, and display differential tissue specific expression. Altogether the TIMP family members inhibit all MMPs as well as exert inhibitory action on certain members of ADAM (A disintegrin and metalloprotease) and ADAM-TS (A disintegrin and metalloprotease with thrombospondin motifs) families [6] . MT-MMPs exhibit specific selectivity in sensitivity to the four TIMPs. Unlike other TIMPs, TIMP-3 is insoluble and binds to ECM both in vitro and in vivo. The balance of activities between TIMPs and MT-MMPs are important for tissue homeostasis, and the disruption of this balance can be implicated in cancer progression [6] . TIMP-2 binding to MT-MMP promotes proMMP2 activation or inhibits MT-MMP catalytic activity, thereby affecting also the MT-MMP turnover and amount of active enzyme at the cell surface [5, 34, 35] . Experimentally, the differential sensitivities of MT-MMPs to TIMP inhibition can be used for differentiating the activities of type I TM MT-MMPs (insensitive to TIMP-1) from those of the soluble or GPI-anchored MMPs (both inhibited by TIMP-1; all three inhibited by TIMP-2) [36] [37] [38] .
The cross-cancer overview on TIMPs (Fig. 3) indicates that similarly to the characteristic MMP14 and TIMP-2 co-expression in embryogenesis [39] , both genes are abundantly expressed in cancers such as sarcomas and melanomas (TCGA; Fig. 3 ). The distinctively high TIMP-4 expression in brain tumors (TCGA) is in turn consistent with the high expression in e.g. cerebellum and peripheral nervous system ganglia (ist.medisapiens.com [13] ). Of note, regarding the ratios between MTMMPs and TIMPs, is that TIMP family exerts selectivity between different MT-MMPs and functional outcomes in proteolysis regulation. Since TIMP-4 does not participate in proMMP2 activation by MMP14, but rather inhibits MMP14 autocatalytic activity [40] , TIMP-2/TIMP-4 balance has been suggested to determine the net degradative potential of MMP14 or other MT-MMPs according to distinct TIMP binding specificities and inhibitory potential [35, 40] . Moreover, TIMP actions 
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BBA -Molecular Cell Research 1864 ) 1974 -1988 are not solely towards MT-MMP inhibition, as these inhibitors also regulate soluble MMPs, ADAMs, and ADAM-TS proteases, and have protease-independent functions [6] .
Transcriptional MT-MMP regulation via EMT, inflammation, cytoskeleton-ECM axis and hypoxia
The variable responsive elements and predicted transcription factor (TF) binding sites in MT-MMP promoters are consistent with their differential expression patterns and transcriptional regulation in distinct cancers (see e.g. Lohi et al. (2000) Gene 242:75-86 and GeneCards; www.genecards.org; for chromatin-immunoprecipitation based TF binding site predictions). In general, MT-MMP transcription can be coupled to tumor suppressor pathways. Frequent mutations or cancerspecific repression of the tumor suppressors will release MT-MMPs from transcriptional repression, as reported recently for MMP24 induction in association with increased lung cancer metastasis [41] . Moreover, the tumor suppressor retinoblastoma (Rb) transcriptional pathway controls cell-cycle progression, and has been linked to tumor progression and metastasis involving broad regulation of MMPs. Essentially all human MMP promoters contain predicted binding sites for E2F, and after Rb inactivation, both MMP14 and MMP15 promoters have been shown to be responsive to E2F [42] .
The overall transcriptional regulation of MT-MMP expression is mediated by several growth factor and cytokine signaling pathways (e.g. Wnt/β-catenin, interleukin-JAK-STAT, TNF-α/NF-κB and TGF-β-Smad), which are associated with the induction of epithelial-tomesenchymal transition (EMT), and can trigger the expression of MTMMPs and soluble MMPs as shown in numerous studies [43] [44] [45] [46] [47] . The MT-MMP inducing pathways converge on the level of EMT-associated TFs, such as Snail, Zeb, and Twist TF families, which harbor the master regulators of EMT to drive characteristic cellular changes, such as repression of E-cadherin and major cytoskeletal reorganization related to adhesion [48, 49] . Snail TFs, for instance, repress E-cadherin and increase MMP14 and MMP15 expression with reported impact also in MMP17 expression under hypoxia [50] [51] [52] . Disruption of E-cadherin based junctions releases associated β-catenin, which can be stabilized by the co-activators of Wnt signaling pathway to enable its nuclear translocation [49] . Alternatively, activating mutations of β-catenin allow its translocation to the nucleus, leading to activation of TCF-4/ Lef TFs that can induce MT-MMPs in cancer [53] [54] [55] . In this manner growth factor and inflammatory cytokine signaling pathways can convergently induce EMT programs and increase MT-MMP expression (Fig. 4A ), which in turn reinforces the loss of cell junction integrity to further drive mesenchymal cell phenotype and functions [49] .
Additionally, MT-MMP promoters contain unique properties that respond to various biochemical and structural cues dictated by the TME to contribute to the cell-type specific MT-MMP expression in cancer (Fig. 4A) . Indeed, instead of dominant regulation by growth factors and cytokines alone characteristic to some soluble MMPs, MMP14 expression is uniquely regulated by cytoskeleton-ECM interactions. Already early studies have demonstrated that three dimensional collagen environment, signaling pathways initiated through integrins, as well as actin cytoskeleton remodeling sensitively regulate MMP14 expres- 
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BBA -Molecular Cell Research 1864 ) 1974 -1988 sion in invasive cancer cells and normal cells (Fig. 4A ) [56, 57] . Intriguingly, type I collagen, a major MMP14 substrate in the ECM, is a powerful inducer of cell-surface MMP14 expression e.g. through TGF-β-Smad signaling [46, 58] . In addition to the regulation by the growth factors, or mechanical and physical tissue properties, the growth of the tumors is sensitive to the generation of hypoxic regions as the cancer cells proliferate rapidly, and abnormal tumor vasculature fails to deliver enough oxygen. Hypoxia inducible transcription factors (HIF) coordinate multilevel adaptation of cancer cells to hypoxia including promotion of EMT programs [59] . The increased expression of MMPs is associated with hypoxia and regulated in a HIF-dependent manner (Fig. 4A ). MMP14 is transcriptionally upregulated by HIF-2 in carcinoma cells with hereditary loss of von Hippel-Lindau (VHL), a protein that directs HIF for degradation under normoxia [60] . MMP15 has been recognized as HIF-1α responsive gene in pancreatic, non-small cell lung, and cervical cancer cells [61] . Altogether, the pathological responses of MT-MMP genes to the multilevel external stimuli appear more controlled than those of other MMPs, in part due to membrane tethering that sets limits for the overproduction. Nonetheless, it is fascinating to observe that MT-MMPs can be such multifaceted responders to TME's biochemical and physical stimuli, which in turn can alter invasive phenotype of cancer cells, thereby demonstrating that these peculiar cascades tie together several hallmark capabilities of cancer.
MT-MMP regulation by microRNAs and secondary structures
The features controlling post-transcriptional regulation of MT-MMP expression can also lie within a noncoding sequence or structure of the RNA transcript. Sequences in mRNA 3'UTR region serve as complementary binding sites for microRNAs (miRNAs), the trans-acting elements that reduce stability of mRNA and inhibit translation. Although the miRNA functions in the context of TME remain as yet incompletely understood, data on miRNA-mediated regulation of MTMMPs and cell phenotypes is accumulating rapidly with indications of either induction or downregulation of specific miRNAs in cancer cells. As indicated in the overview of the conserved binding sites for common miRNAs in MT-MMP 3'UTR regions, both MMP14 and MMP15 tran- Fig. 4 . Overview of the microenvironmental regulation, localization and functions MT-MMPs in TME. Microenvironmental cues of the dynamic TME are key inducers of MT-MMP expression but also subject to major changes upon MT-MMP action. A) MT-MMP expression is responsive to ECM composition and to rearrangements of the actin cytoskeleton [1, 46, 58] . Inflammatory mediators and growth factors of the TME are pivotal inducers of MT-MMP expression and likewise also markedly altered by MT-MMP cleavages [1, 44, 46, 47] . MT-MMPs are associated with characteristic metabolic features of cancer cells (Warburg effect), and induced by the hypoxic conditions in the growing tumor [171] . B) MT-MMPs are localized to actinbased structures called invadosomes for spatially coordinated matrix degradation to support invasion [77, 91] . Localization of MT-MMPs is not limited to cell membrane as they can be sorted to extracellular vesicles and soluble shed forms have also been described [2, 84, 85] . C) Degradation of ECM components and cleavages of the cell adhesion molecules by MT-MMPs fundamentally shape the invasion and growth pattern of the tumor [1, 2, 4, 126] . MT-MMPs alter signalling in the TME by shedding membrane proteins e.g. receptor tyrosine kinases (RTK) and soluble, membrane-anchored or ECM sequestered ligands [2, 4, 38, 126] .
scripts contain less than ten conserved binding sites for the common miRNAs (Table 1 ). MMP14 has been identified as a target for miRNAs, such as let-7, miR-22, and miR181a-5p, typically down-regulated in cancer (see e.g [46, 62, 63] .), and MMP15 is a target for miR-148a, also generally down-regulated in cancer, but up-regulated in a subset of non-small cell lung cancer [64] . MMP16 instead contains an exceptionally long 3'UTR with estimated 40 conserved miRNA binding sites providing means for complex regulation of expression. Indeed, the reported MMP16-targeting miRNAs include miR-145, miR-146b, miR-328, and miR-200b, whose altered expression has been linked to the malignant properties in different types of cancers [65] [66] [67] [68] . Interestingly, the 3'UTR of MMP24 likewise contains several conserved miRNA regulatory sites (Table 1) with as yet undefined importance, whereas MMP17 and MMP25 transcripts lack predicted miRNAs binding sites.
Moreover, MMP16 has a unique suppressive translational control mechanism at 5'UTR of mRNA upstream of the initiation codon. The guanine rich 20-nucleotide sequence composed of purines forms an exceptionally stable intramolecular G-quadruplex structure that inhibits the translation of MMP16 mRNA [69] . However, it remains undefined whether or how this inhibition is altered in cancer.
Intracellular trafficking and cell-surface localization of MT-MMPs
Proteolytic enzymes functioning at the cell surface as membranetethered proteins require multilayered mechanisms to control the proper amount and localization of active enzyme. Among MT-MMPs, MMP14 has been the most widely studied also regarding the regulation of activity and localization. All MMPs are synthesized as latent zymogens containing an N-terminal globular prodomain that protrudes to the protease active site to maintain latency [71] . Zymogen activation of MT-MMPs occurs constitutively in the trans-Golgi network by furin or other proprotein convertase mediated removal of the N-terminal prodomain upon trafficking from the endoplasmic reticulum to the cell surface [72] [73] [74] . Thereafter, the dynamic regulation of the active cell surface enzyme can be achieved e.g. by internalization and recycling of the MT-MMP bearing vesicles.
For the membrane-tethered MT-MMPs, vesicular trafficking is a major regulatory system that involves different pathways of internalization, recycling and sorting collectively controlled by numerous molecules. Alterations in any of them can markedly affect MT-MMP trafficking and proteolytic activity with subsequent consequences on cell phenotype or cancer progression [75] [76] [77] [78] . Among MT-MMPs, MMP14 is the most widely studied also regarding the regulation of activity and localization. On the cell surface, MMP14 localizes in both caveolin and clathrin coated pits, and both endocytosis pathways can be used for internalization [79, 80] . The intrinsic differences in amino acid sequences of type I TM MT-MMPs crucially determine the prerequisites for adaptor protein interactions along the trafficking and sorting pathways. For example, a common motif (LLY) in the MT-MMP CT is important for the protease internalization and dynamics, but the CT sequence of MMP24 diverges, and thereby different CT residues and interactors mediate internalization and recycling of this MT-MMP [81] . Moreover, studies on the dynamics of internalization and recycling of GPI-anchored MMP17 in breast cancer cells identified the Rho GTPase dependent endocytic CLIC/GEEC pathway (clathrin-independent carriers/GPI-enriched early endosomal compartments) as a major internalization pathway highlighting the distinct features of GPI-anchored MT-MMP regulation [82] . Vesicular trafficking may further direct MT-MMPs to lysosomal degradation [83] or to extracellular vesicles [84, 85] . Endosomal MMP14 has been found to be sorted to exosomes for extracellular release in fibrosarcoma and melanoma cells (Fig. 4B ) [84] . Moreover, MMP14 is sorted to shed microvesicles budding outwards from the plasma membrane in ovarian cancer (Fig. 4B) , and these MMP14-loaded vesicles have been suggested to help cancer cells to maintain ameboid-like invasion [85] . The putative functions of MT-MMPs in extracellular vesicles warrant further studies in this blooming field of cancer research (Fig. 4B) .
Extensive evidence has accumulated to support the importance of MT-MMP microtubular vesicular trafficking to specialized membraneprotrusions called invadopodia. These are the most comprehensively characterized structures responsible for matrix degradation in malignant cells. Invadopodia are composed of actin-rich core surrounded by scaffold and adhesion proteins [77] , and they can be formed in response to e.g. growth factor and integrin signaling [77, 86, 87] (Fig. 4B) . Contact with macrophages has also been found to initiate invadopodia assembly in tumor cells disseminating through blood vessel endothelium [88] . The key proteins forming invadopodia include cortactin and neural Wiskott-Aldrich syndrome protein (N-WASP), Tyr kinase substrate with four SH3 domains (TKS4), Tyr kinase substrate with five SH3 domains (TKS5), and MMP14 [77, 86] . Direct MMP14 CT binding to actin, and the actin-binding protein palladin have been described as means for invadopodial targeting of the protease [89, 90] . The multistep invadopodial assembly and mechanisms of MMP14 traffic therein are discussed in exact molecular details elsewhere [77, 78, 86, 91] .
Some aspects of the multifaceted functions of distinct MT-MMPs in the membrane and towards the ECM or cytoskeleton have, however, remained incompletely understood. For instance, specific membrane islets enriched for MMP14 have recently been characterized as sites for the re-emergence of podosomes which are invadopodia-related invadosome structures in macrophages [91, 92] . These islets serve as structural memory devices independent of MMP14 proteolytic activity [92] (Fig. 4B) . Besides invadosomes, the cells of mesenchymal origin including CAFs have been reported to use tubular/reticular organization of activities towards ECM [93] (Fig. 4B) . The differential mechanisms of matrix degradation and remodeling by epithelial cancer cells and stromal cells have been suggested to amplify the invasive capacity of malignant transformed cells [93] .
Oligomerization and autocatalytic processing
Oligomerization and autocatalytic processing add another level for MT-MMP regulation at the membrane [2, [94] [95] [96] . MMP14 oligomerization and dimerization via homotypic hemopexin domain interactions occur dynamically at the leading edge of invading cells, and is [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] controlled by inside-out signal in response to actin cytoskeletal reorganization through the activity of small GTPases [2] . These processes can be further regulated by MMP14 CT, and have been associated with regulation of both collagenolysis and proMMP2 activation [2, [94] [95] [96] . Upon cell invasion, dimerization via hemopexin-like domain interactions has been suggested to facilitate correct positioning of MMP14 molecules for fibrillar collagen degradation, although these mechanisms still remain incompletely understood [2, 97, 98] . Besides type I TM MT-MMPs, oligomerization has also been described for GPI-anchored MMP17 and MM24 via intermolecular disulfide bond formation between stem regions linking hemopexin domain to GPI-anchor [99, 100] . Dimers/oligomers also facilitate inactivating autocatalytic cleavages of the juxtaposed MMP14 molecules [94, 96] . In these autocatalytic events MT-MMP cleaves an adjacent MT-MMP molecule in the catalytic domain or between the catalytic and hemopexin domain by a process accelerated upon increasing expression [5, 7, 34, 94, 96, 99, 101, 102] . Co-incident with the release of soluble forms, autocatalytic cleavages generate inactive membrane-bound MT-MMP fragments that can alter MT-MMP activities or the internalization of fulllength protease, thereby regulating the cell surface MT-MMP expression and activity [103] [104] [105] .
Other MT-MMP regulatory proteins at the membrane
MT-MMPs also interact with and are regulated by other transmembrane co-factors, whereby the net effect in cancer progression is likely context-dependent and unclear. The plasmamembrane invaginations called caveolae are abundant in caveolin-1 that forms a scaffold for the assembly of signaling complexes. MMP14 localizes into caveolae at least in endothelial cells, fibrosarcoma, and glioblastoma cells, and interacts with phosphorylated caveolin-1 [106, 107] . Little is known about other MT-MMPs in specific lipid domains, but the GPI-anchored MT-MMPs have been found condensed to the related, flat glycolipidenriched membrane microdomains [7] . Since proMMP2 activation and autocatalysis occur in caveolae, and MMP14 is directed to endocytic pathway from the caveolae in tumor and endothelial cells to regulate cell surface protease activity [79, 106, 108] , localization of MMP14 into caveolae is an additional way of regulating and coordinating MMP14 functions. The recruitment of MMP14 into caveolae signaling complexes possibly alters TME-relevant signaling in broader extent than currently appreciated, either to suppress [106, 109] or to promote tumorigenic function [110] . For example, platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) are enriched in caveolae membranes, and known to crosstalk with MTMMPs [110] [111] [112] . Caveolae complexes could also serve as activity switch platforms as shown e.g. in endothelial cells where vascular endothelial growth factor (VEGF) induces dissociation of VEGFR2 from caveolin-1, whereby MMP14 can instead be recruited to promote tubulogenesis [107, 113] .
RECK (reversion-inducing-cysteine-rich protein with Kazal motifs) is a membrane protein that inhibits the activity of MMP14 as well as MMP2 and MMP9. RECK is a GPI-anchored glycoprotein inhibiting MMP14 locally at the same cell membrane. The frequent downregulation of RECK ("RECKlessness") [114, 115] is a feature of malignant tissue, and therefore the regulatory impact of RECK on MMP14 is suppressed during cancer cell invasion and tumor progression. Testican-1, testican-2, testican-3 and its splicing variant N-Tes are chondroitin/ heparan sulphate proteoglycans that can inhibit proMMP2 activation by either MMP14 or MMP16. Testicans are typically expressed at lower levels in cancerous tissues than in normal tissues [116, 117] .
Tetraspanins are ubiquitously expressed molecular organizers at cellular membranes implicated in cancer invasion and metastasis [118] . Tetraspanins associate with several types of membrane proteins to form multimolecular lipid-protein membrane complexes known as tetraspanin-enriched microdomains (TEMs) [118] . Recruitment of proteins into TEMs can alter their activity and functions notably, and MT-MMPs are known candidates in tetraspanins webs [83, [119] [120] [121] . Studies on clinical cancer patient data and animal models have linked specific tetraspanins to poor cancer prognosis and metastasis (reviewed in [122] ). However, the relevance of plausible tetraspanin regulation of MT-MMP activity remains as yet unclear in cancer.
MT-MMP functions in TME communication
ECM degradation
Collectively MMPs can degrade virtually all components of the ECM, and vast amount of literature summarizes these events as crucial for cancer growth and invasion (reviewed in [ 1,2,123] ). Membraneanchorage of the MT-MMPs concentrates their proteolytic activity to the cell surface and invadosomes, and the distinct MT-MMPs possess somewhat divergent pericellular ECM degradation abilities (Fig. 4C) . While fibronectin, fibrinogen and denatured collagen (gelatin) can be considered as broad substrates for the MT-MMPs, the critical and the most extensively characterized proinvasive MT-MMP functions include breaching of tissue barriers by degradation of interstitial type I collagen and basement membranes (BM) [1] [2] [3] 124] . Essentially, both MMP14 and MMP15 can cleave pericellular native type I collagen, which alone is considered sufficient to enable invasion of both cancer cells and stromal fibroblasts [125] . MMP16 degrades and drives invasion in provisional fibrin matrices, and also cleaves collagen type III and IV, but is a poor type I collagenase [1, 2, 104, 126] . For driving efficient BM invasion of cancer cells, MMP14, MMP15 and MMP16 are all active and sufficient, whereas MMP17, MMP24 and MMP25 do not display native BM remodeling activity [1] . However, compared to the widely expressed MMP14, considered as a major cell surface collagenase, the restricted expression of the proinvasive MMP15 and MMP16 activity may limit their in vivo significance in cancer [125] .
MMP24 substrates in turn include heparin/chondroitin sulphate proteoglycans, in addition to gelatin and fibrinogen, whereas no collagen cleavage ability has been described [2, 7] . The GPI-anchored MMP17 is distinctive in respect to its limited ability to degrade ECM components. However, the other GPI-anchored MT-MMP, MMP25 has been reported to degrade type IV collagen, in addition to gelatin and fibronectin, suggesting that the mechanism of membrane anchorage may not dictate the ECM degradation specificity [7, 37] .
Proteolysis of the BM components such as laminins and collagen type IV has further been associated with cancer invasion by revealing neoepitopes, or matricryptic sites, which become unmasked and may shift the integrin-mediated interactions [3, 127] . This creates complex feedback signaling mechanisms between the BM and cancer cells [127] [128] [129] [130] . Some discrepancies have been reported concerning the functions of MT-MMPs and indirect contribution of MT-MMP-activated soluble MMPs, mainly MMP2, in BM degradation [1] . However, different tumor cell types may combine and create additive interplay between their proteolytic activities in vivo depending on the TME, as it has also been suggested that MMP14-dependent tumor growth benefits from the stromal-derived MMP2 to facilitate breakdown of BM-like structures [131] .
Activation of soluble MMPs and membrane proteolytic cascades
At the cell membranes, MT-MMPs regulate the activities of soluble MMPs, other MT-MMPs and the related metzincin proteases of ADAM and ADAM-TS families either with activating or inactivating effect [3, 132] . MMP14 is the main activator of proMMP2 through a multistep process which also requires TIMP-2 [2, 133] . Stepwise formation of a ternary complex between MMP14-TIMP-2-proMMP2 positions the prodomain of proMMP2 optimally to allow the prodomain cleavage by TIMP-2-free molecule of MMP14 [2, 133] (Fig. 4C) . Following the prodomain cleavage, MMP2 is autocatalytically cleaved to function as a S.P. Turunen et al.
BBA -Molecular Cell Research 1864 (2017) 1974-1988
fully activated protease [134] (Fig. 4C) . TIMP-2 has a dual function in MMP2 activation: at low concentrations it induces proMMP2 activation by promoting the binding of proMMP2 to MMP14, whereas at high concentrations it prevents the activation by inhibiting the proteolytic MMP14 activity [133] . Moreover, MMP14 can activate proMMP13 [135] and co-operate with plasmin in proMMP2 activation [136] . Proteolytic regulation of one MT-MMP by another MT-MMP has been shown at least between MMP14 and MMP16 in melanoma [104, 126] . MMP16 forms complexes with MMP14 at the cell surface and cleaves it generating 43-37 kDa fragments, which restricts collagenolytic ability of MMP14. This results in phenotypic change from invasive to expansive growth of melanoma [104, 126] . The other examples of protease inactivation by MT-MMPs are cleavages of ADAM9 [132] and ADAM15 [137] by MMP14 at the plasma membrane of osteoblasts. The cleavage of ADAM9 prevents ADAM9-mediated inactivation of FGFR2 signalling in calvarian osteogenesis [132] . Although similar MMP14-mediated ADAM cleavages have not yet been described in cancer cells, these results suggest that aside from the wellestablished protease activation cascades, MT-MMPs can control the inactivation of other pericellular proteases [137, 138] .
Shedding of membrane proteins
MT-MMPs are pivotal regulators of both the membrane-attached proteins and secreted factors in spatially and temporally controlled manner (Fig. 4C) . Cancer cell -TME communication, migration, and angiogenesis are modified by cleavages of the membrane-bound proteins including signaling receptors, and by activity regulation of other proteases, as accumulating evidence in multiple aspects of cancer shows [26] . Our understanding of the MT-MMP substrates is increasing with the systematic mass spectrometry analyses of the degradome [139] (see e.g. TopFIND for comprehensive lists of protease substrates and cleavage sites [140] ). MMP14 can cleave a number of cell surface proteins and receptors such as CD44, ADAM9, syndecan-1, αv, α3, and α5 integrin subunits [2, 5, 141] . Based on mass spectrometry results, the MMP14 degradome further includes e.g. neutrophil chemokine IL-8, secretory leukocyte protease inhibitor, pro-tumor necrosis factor α, death receptor-6, and connective tissue growth factor [139] . Low density lipoprotein receptor -related protein 1 (LRP1), also known as α-2 macroglobulin receptor or CD91, is cleaved by MMP14 among multiple other proteolytic regulators, leading to inactivation of the ligand-binding function of this scavenger receptor [5, 142] . As LRP1 captures, internalizes and clears MMP2 and MMP9 from the extracellular milieu, the MMP14 cleavage of LRP1 contributes to diminished clearance of these soluble MMPs and potentiates their proteolytic activity [5] . MMP15, MMP16 and MMP17 can also cleave LRP1 [5] . MMP16 has also been described to cleave several cell surface proteins, such as CD44, neural cell adhesive molecule L1 (L1CAM), endogenous Nogo-66 receptor 1 (NgR1), syndecan-1, and tissue transglutaminase, but the biological functions of these cleavages have remained largely unknown [5, 33, 126, 141] .
Signaling crosstalk
Since the first identification of MT-MMP-RTK (receptor tyrosine kinase) complex between MMP14 and PDGFRβ in vascular smooth muscle cells [111, 142] RTK-MMP14 crosstalk has also been acknowledged in cancer. For instance, a systematic kinome screen for MMP14-mediated MMP2 activation has identified RTKs from fibroblast growth factor receptor (FGFR) and erythropoietin producing hepatocellular (Eph) RTK families as unique MMP14 regulators [45] . Both of these RTKs are upregulated or altered in cancer. EphA2 is the Eph-receptor identified as a regulator of MMP14 activity and expression by the kinome screen [45, 143] . Subsequent studies established that MMP14 cleaves EphA2 when interacting in the same membrane complexes (Fig. 4C ), leading to a switch from collective to single cell invasion via FRS2-Src signaling coupled to RhoA activation in basal-like breast carcinoma [4, 143] , and increased oncogenic EphA2 signaling in ovarian cancer [144] . The FGFR4-R388 polymorphic variant linked to poor prognosis in cancer stimulates MMP14 activity, and increases collagen invasion and xenograft tumor growth, unlike the alternative FGFR4-G388 variant or other members of the FGFR family [45, 145] . MMP14 modulates FGFR-signaling in cancer cells additionally by diminishing the low-affinity, heparan sulphate -based binding sites of FGF-2 required to ignite FGFR2 signaling [138] . Interestingly, control of ligand availability through MMP14-mediated processing of growth factor binding sites is indeed a distinctive regulatory mechanism of e.g. FGFR2 signaling [138] . FGFR cleavages by MMP14 have not been observed in cancer cells, although FGFR4 and FGFR1 levels are downregulated in the presence of overexpressed MMP14 in breast carcinoma cells [45, 138] .
The GPI-anchored MT-MMPs can also relay outside-in signals that promote tumor progression, but to date relatively little is known about these cascades. MMP17 promotes tumor cell proliferation independent of its proteolytic activity by interacting with EGFR and inducing receptor activation and signaling, pinpointing yet another crosstalk mechanism between an MT-MMP and RTK [112] . Discoidin domain receptors (DDRs) are unique RTKs that are activated in response to collagen. MMP14, MMP15 and MMP16 mediate ectodomain shedding of DDR1, and regulate collagen-induced receptor signaling, whereas the GPI-anchored MMP17 and MMP25 do not cleave DDR1 [146] . Wnt/ planar cell polarity protein-tyrosine kinase-7 (PTK7) is a pseudokinase cleaved by MMP14, and a fine balance between protease activity and PTK7 levels has been suggested to be pivotal for both normal embryogenesis as well as cancer cell invasion [147] . Signaling via MMP14-VEGFR2 complex instead leads to increased VEGF-A transcription in breast cancer cells [148] . MMP14 has also been reported to shed cryptic angioinhibins, such as the N-terminus of brain-specific angiogenesis inhibitor 1 (BAI1), an orphan GPCR-type transmembrane protein, to yield a soluble vasculostatin-40 fragment that inhibits angiogenesis [149] . Additionally, various GPCRs can activate MMPs depending on the cell type, but precise mechanisms of this activation have not been elucidated [150] . Moreover, GPCRs can transactivate RTKs, in particular EGFRs, and metalloproteases are crucially involved by shedding growth factors [151] (Fig. 4C) . Direct regulation of MMP14 by heterotrimeric G proteins has been described using isolated membrane fragments [150] , and the downstream cascade has been investigated e.g. in lung cancer; MMP14 cleaves membrane bound heparinbinding EGF-like growth factor (HB-EGF), and the released growth factor activates EGFR [152] (Fig. 4C ). In conclusion, MT-MMPs are increasingly appreciated as regulators of cell-TME communication by crosstalk with RTKs, in addition to their activities on ECM and other pericellular proteins.
Regulation of cancer cell-ECM interactions and fibrotic responses in cancer
MT-MMPs provide cancer cells with multiple mechanisms to remodel TME and promote cancer progression. As an interstitial collagen degrading enzyme, MMP14 has been paradoxically associated with increased fibrosis in breast and pancreatic carcinoma via the induction of TGF-β signalling and subsequent collagen production by the stromal cells [46] . MT-MMPs contribute to fibrotic responses by regulating the growth factor availability in the TME. For instance, MMP14 releases latent TGF-β complexes from sub-endothelial matrix for activation by neighbouring cells [38] , and co-operates with αvβ8 integrin in the proteolytic activation of latent TGF-β1 [153] . Since integrins function as ECM receptors and intracellular regulators of actin cytoskeleton dynamics, their functional interplay with MT-MMPs provides an important response mechanism for the TME communication [57, 154] . Indeed, MMP14 associates with multiple integrin molecules, e.g. β1 or αvβ3 integrins, in an ECM-dependent manner [155] , whereby integrin clustering stimulates MMP14 expression in endothelial and cancer cells, and has been linked to increased proMMP2 activation in numerous studies (reviewed in [154] ).
In addition to the interplay with integrin-mediated adhesion signaling, MMP14 expression is elaborately coupled to prosurvival signals upon fibrotic/desmoplastic responses in cancer [1, 46, 156] . Native type I collagen is a major component of the reactive tumor stroma, which is degraded only by a limited set of MMPs [157] . In the fibrotic TME, cancer cells can overcome the growth restriction imposed by the intact collagen barriers by coupling increased MMP14 collagenolytic activity to invasiveness and suppression of proapoptotic signaling mediated by collagen-activated receptor DDR1 [1, 46, 156] . These pathways highlight the contribution of MMP14 in the communication between cancer cells, stromal cells and ECM, which allows cancer growth and apoptosis evasion upon the development of fibrosis with impact on cancer aggressiveness, as well as on the penetration of chemotherapeutic drugs into the tumors.
MT-MMPs in tumor angiogenesis
The fine balance between proteases and their inhibitors controls different processes of angiogenesis, including sprouting, vessel stabilization and regression. MMP14-deficient mice exhibit severe defects in angiogenic responses, highlighting the essential functions of MMP14 in the angiogenesis processes [158] . MMP14 supports both new vessel sprouting as well as pericyte recruitment [111, 159] , cleaves ECM molecules and anti-angiogenic factors, interacts with cell surface molecules, and increases the production of angiogenic factors such as VEGF-A [160] . Growth factor-induced tube formation in vitro requires MMP14 activity, whereas MMP2 is dispensable for the process [11, 15] . Moreover, cancer cell-derived VEGF-A can induce MMP14 expression and tube formation of endothelial cells [161] . MMP14 in turn induces VEGF-A transcription via Src phosphorylation in tumor cells thus promoting tumor vascularization [5, 148, 162] . MMP17 has been likewise linked to intratumoral vascular aberrations and angiogenesis, but this effect has been ascribed to cancer cell MMP17 [17, 163] . Altogether, the vascular stabilization and maturation or leakage are distinctively regulated by different MT-MMPs, which is relevant for cancer progression and may also affect chemotherapy delivery. These aspects of MT-MMPs in tumor angiogenesis are reviewed and illustrated by others [160] .
Emerging concepts in MT-MMP regulation and functions
Intracellular MMP14 functions
While MT-MMPs respond to changes in TME, the induction of MTMMPs in turn regulates various transcriptional programs indirectly in cancer via altered signaling cascades as a result of ECM degradation, or shedding or release of growth factors, signaling receptors, pericellular proteins and adhesion molecules. These types of complex and incompletely understood transcriptional networks are closely linked to MT-MMP function in TME communication. Yet another level to the MT-MMP signaling functions is brought by the CT of type I TM MT-MMPs, which can extend their functions to intracellular signal relay via mechanisms including protein phoshorylation by kinases. MMP14 CT contains a tyrosine residue, which can be phosphorylated by Src kinase with subsequent effects on cell migration [164] . Moreover, a dualspecificity LIM kinase-1 and -2 (LIMK1/2) and NF-κB-inducing kinase (NIK/MAP3K14) have been shown to phosphorylate Y573 on the CT of MMP14 [165, 166] . Threonine phosphorylation at T567 and palmitoylation of C547 in MMP14 CT have also been described [2, 167] , and similar modifications potentially regulate other MT-MMPs. Signals from the extracellular space can also be relayed through MT-MMP molecule via its CT plausibly via proteolysis-independent mechanisms. For example, the binding of TIMP-2 to MMP14 has been shown to induce ERK1/2 and Akt pathway activation leading to increased cancer cell migration and proliferation [168, 169] .
In addition, intracellular proteolytic and non-proteolytic activities of the full-length MT-MMPs have been described, but remain poorly characterized to date. In macrophages, MMP14 has been recognized as a transactivator of gene networks crucial for controlling pro-and antiinflammatory cytokine responses [170] . Whether the nuclear-localized MMP14 is a potent regulator of cytokine responses in TAMs, or contributes to TAM phenotype, remains to be resolved. MMP14 has also been described in the centrosomal compartment where it has been reported to cleave pericentrin, a protein essential for normal centrosome function and mitotic spindle formation, thus possibly linking the MMP14 intracellular proteolytic activity to early events in carcinogenesis [5] .
Altogether, the relative impact of the indirect, intracellular or nonproteolytic regulatory functions of MT-MMPs in the evolving TME can be context-dependent and essentially coupled to MT-MMPs' proteolysismediated modulation of cell-TME interactions in cancer.
Connection to metabolic changes in cancer cells
Due to their multiple protease dependent and independent functions in cellular physiology MT-MMPs can be expected to affect cancer cell's biochemical circuitry far beyond motility. Metabolism of cancer cells utilizes aerobic glycolysis under normoxia, which is known as the Warburg effect, and this is accompanied by HIF-1 being constitutively active despite adequate available oxygen [171] . Interestingly, MMP14 expression is a common feature of the tumor cell lines exhibiting increased glycolytic activity, and forced expression of MMP14 is sufficient to induce the Warburg effect in tumor cells [171] (Fig. 4A) . The underlying mechanism has first been described in macrophages, and involves binding of factor inhibiting HIF-1 (FIH-1) to the MMP14 CT, which directs FIH-1 to interact with Mint3 thus abrogating FIH-1 repression of HIF-1 transcriptional activity [172] .
Moreover, MMP14 has emerging functions as a regulator of tissue homeostasis through effects on energy metabolism balance and autophagy [173] , and the closely related MMP15 is also linked to regulation of adipocyte differentiation [174] . These findings have been established in knock-out animal models, and link MMP14 to biogenesis of white adipose tissue, whereas MMP15 suppresses thermogenic brown adipocytes in the developing mammary gland [174] . However, the plausible effect of MMP15 in tumor tissue adipocytes remains unknown.
Aerobic glycolysis (Warburg effect) has also been linked to defects in mitochondrial oxidative function [175] . The disruption of mitochondrial cytochrome c complex and loss of membrane potential induces oncogenic signaling in multiple ways including induction of MMP16 expression [175] . Therefore, it remains to be established how MTMMPs are coupled to the multilevel changes in cancer or stromal cell energy metabolism to support tumor progression.
Evolving view of MT-MMPs in invasion, tissue colonization and cancer recurrence
The invasion modalities that give rise to metastatic dissemination have been considered to occur largely downstream of EMT, and upon loss of epithelial-like integrity and polarity. The hypothesis that single cells budding from the primary tumor would seed metastases has been challenged by recent lineage-tracing studies that suggest collective invasion of tumor cell clusters as the main culprit towards distant metastases (reviewed in [48, 176] ). Findings from lung and pancreatic cancer models demonstrated that EMT is not required for metastatic outgrowth, but cells that have undergone EMT are more resistant to chemotherapy and give rise to relapses after treatment [177, 178] . Additionally, collagen-induced MMP14 expression has been reported to mediate high mobility group A2 (HMGA2) induction and to increase resistance to gemcitabine in pancreatic ductal adenocarcinoma cells [179] . This also challenges the view on MT-MMPs, especially MMP14 and EMT, for metastasis seeding, recolonization and drug resistance. While EMT and induced MT-MMPs can be essential for the local invasion [52, 77] , metastases can be seeded as collective clusters [48, 176] . MT-MMP proteolytic activity might be suppressed at the centres of these collective clusters and induced at the edges to drive local invasion. The intracolony segregation of MT-MMP activity has been suggested to be beneficial for the outgrowth of cancer [180] , but no consensus exists yet to understand how the transitions between EMT and cohesive growth fluctuate to achieve recurrence. Fine-tuned spatiotemporal alterations and intermediates of epithelial and mesenchymal cell types are suggested ways of reaching optimal prosurvival balance for metastasis and possible recurrence under the selective pressure imposed by chemotherapeutics [48] . To add complexity, tumor cells may switch between the use of microvesicles and invadopodia depending on the microenvironment to facilitate invasion [181] , and MT-MMPs functions are coordinated and localized accordingly [85] . Distinct TME contexts and cell-intrinsic factors affect the pathological significance of the MT-MMPs in controlling signaling and invasion modes [4] . MMP14 cleavage site in receptor tyrosine kinase EphA2 is an intriguing example of the cancer-and cleavage site-specific outcomes for cancer cell invasion modalities. MMP14 cleaves EphA2 leading to a switch from collective to single cell invasion in breast carcinoma, whereas a somatic mutation incapacitates MMP14 cleavage of EphA2 in lung cancer and retains collective growth [143, 182] .
Proteolytic switches and the vascular metastatic route
Metastatic spread of cancer occurs mainly via vascular or lymphatic system. Blood vessel invasion requires active permeabilization of blood vessels by tumor cells, whereas lymphatic vessels with discontinuous basement membrane and intraendothelial channels may permit passive tumor cell passage [48, 126] . Tumor cells invading in single cell manner have been shown to intravasate efficiently into blood vessels, while cells engaging in collective invasion enter lymphatic vessels more easily [183] . However, recent data indicates that also circulating tumor cell clusters can reversibly reorganize into single chain-like patterns to traverse very narrow blood vessel confines [184] , thereby emphasizing the role of multicellular clusters in seeding distant metastases.
Although MMP14-mediated collagen degradation has been widely associated with cancer progression, MMP16 induces aggressive phenotype of melanoma by reducing MMP14-dependent collagen degradation and cell-cell dissociation via proteolytic regulation of MMP14 and L1CAM [126] . This leads to reduced blood vessel invasion, increased cell-cell adhesion, and growth of melanoma cells as expansive nests surrounded by collagen bundles, and instead, increases invasion to lymphatic vessels [126] . Interestingly, MMP14 is also an inhibitor of lymphangiogenesis via its ability to shed LYVE-1 on lymphatic endothelial cells [185] . The downregulation of MMP14 could thus induce tumor lymphangiogenesis and lymphatic invasion.
Targeting MT-MMPs
Since MT-MMPs are matrix degrading enzymes tethered at the cell membrane to coordinately breach tissue barriers for cancer invasion, they have been a tempting target for inhibitor development. Several attempts to target MMPs to prevent cancer progression have succumbed to poor success and adverse side effects, such as musculoskeletal pain and inflammation [186] . Small molecule MMP inhibitors lack the required level of specificity because the catalytic mechanism and the catalytic domain fold are highly conserved throughout the MMP family. Therefore, the resulting broad MMP inhibition causes severe side effects or blocks tumor-suppressive MMPs such as MMP3, -8 and -12 [186, 187] . As MT-MMPs exert changes in cellular functions also independently of the proteolytic activity, even via intracellular CTs, the MT-MMP domain to target has to be carefully considered and validated in cancer progression [188] .
To overcome the limited specificity of small molecule inhibitors, specific antibodies have been engineered as potential therapy approaches to prevent activities of MMP14 [186] . The earliest attempts used catalytic or hemopexin domains as antigens to screen phage display libraries. DX-2400 is a human Fab (antigen-binding fragment) antibody selected against MMP14 catalytic domain, and it blocks proMMP2 processing on tumor and endothelial cells, likewise inhibits angiogenesis, and diminishes formation of metastatic lesions [189] . A human recombinant scFv (single chain variable fragment) selected against the hemopexin domain of MMP14 inhibits angiogenesis and invasive capacity of cancer cells in model systems in vitro, whereas the in vivo functionality has not been demonstrated [190] . Many of the characterized anti-MMP14 antibodies targeting exosites outside the catalytic cleft lack proven efficacy in preventing metastasis seeding. Improved approaches have taken advantage of the early-stage screening of the clones against cell-membrane bound MMP14 in contrast to isolated MT-MMP domain antigens. An Fc-scFv MMP14 antibody has been elaborately engineered using the whole ectodomain of MMP14 for initial screening of phage display library followed by affinity-maturation. These affinity maturated Fc-scFv MMP14 antibodies efficiently inhibit tumor growth and abrogate metastases in breast cancer xenograft model [191] . In parallel, attempts to target MMP14 catalytic site have exploited mimicking the structure of TIMP-2 inhibitor that inserts a long and flexible loop into the protease active site. Human Fab (antigen-binding fragment) library, exhibiting especially long and flexible (23-27 amino acids) heavy chain complementarity determining regions, allowed the selection of a Fab that efficiently prevents lung metastases of mouse melanoma cells [191] .
Miniaturized MMP14 antibodies (scFv or diabody) conjugated to radiolabel have also been used for imaging MMP14 distribution in tumor tissue [192] , and conjugation of commercial MMP14 antibody to PET-tracer has been used to assess tumor progression in GBM animal models. The MT-MMP-based imaging offers interesting venues for detecting small or micrometastatic tumors in the early stages [188, 193] . Moreover, MT-MMPs proteolytic activity and induction in tumors can potentially be harnessed to increase precision of chemotherapy by synthesizing pro-drugs that contain MT-MMP cleavage sites to generate active compound at TME [188] . Advances have also been made in the development of more specific chemical compounds to inhibit MMP14 [194] , and a compound selectively targeting MMP14 hemopexin domain efficiently reduces xenograft tumor growth [195] .
To date, our knowledge on the interconnected proteolytic networks driving cancer is still incomplete. Proteolytic cleavage cascades are regulated by even other proteases within the same family as exemplified by MMP16 post-translationally regulating MMP14 [104, 126] . Cleavages of protease inhibitors such as serpins by metalloproteases can release the activity of another type of proteases, and these inducible, interactive connections between proteases lead to unpredictable systemic and cellular outcomes when one factor is altered [187] . Targeting one MT-MMP evidently shifts the balance of highly dynamic and responsive proteolytic network towards unpredictable direction in the context of cancer progression, regression or dissemination even though studies on MT-MMP inhibition broaden our knowledge on the vast array of targets constantly [187, 196] .
Conclusions
MT-MMPs came into the limelight of cancer research because of their ability to degrade ECM, most importantly type I collagen, and support cancer cell invasion. During the tumor initiation and metastatic cascade, MT-MMP functions contribute not only to invasion but also to growth and survival that are equally necessary for cancer progression. To date, the multifaceted inducers of MT-MMP functions in tumor cells have been discovered widely enough to appreciate MT-MMPs as signaling proteases responsive to the TME communication. Metastatic S.P. Turunen et al. BBA -Molecular Cell Research 1864 ) 1974 -1988 cancer has remained essentially incurable despite development of therapeutic regimens to target several hallmark capabilities of cancer, including invasion. As the emerging evidence suggests, the interactions of diverse cell types regulate the proteolytic network in the TME, and in the course of cancer progression different cell types spatiotemporally fine-tune the cellular proteolytic machinery to dynamically modulate TME [26, 93] . The different key aspects of cancer, such as changes in tumor energy metabolism, immunosurveillance, and the intrinsic and acquired drug resistance, are to be tackled involving the plausible contribution MT-MMPs [175, 179, 197] . Although cancer invasion into interstitial stroma and tumor cell intravasation have been extensively studied in terms of MT-MMP functions, the proteolytic regulation and MT-MMPs in e.g. cancer cell homing to metastatic niches, tumor recurrence and drug resistance remain to be resolved. Despite challenges in targeting therapies that solely limit to inhibition of MT-MMP catalytic activity, the induction of MT-MMPs in cancer can be harnessed for early diagnostic detection and improved therapy efficiency by utilizing MT-MMPs as biomarkers or proteolytic pro-drug activators [188] .
Transparency Document
The http://dx.doi.org/ associated with this article can be found, in online version.
